News

Work in Progress on Challenges of Minority Representation in CF Trials

Proper representation in clinical trials has long been a challenge for minorities with rare diseases like cystic fibrosis (CF), risking — and often leading to — inequities in care and fewer effective treatments for these patients. To this end, members of the CF community, including patients, researchers, physicians, and…

Metal in Source Water Tied to NTM Infection in Patients in Colorado

Source water levels of a metal called molybdenum is a significant environmental risk factor for nontuberculous mycobacteria (NTM) infection among people in Colorado with cystic fibrosis (CF), a database study focused on that state reported. NTM infection, caused by Mycobacterium abscessus (M. abscessus), is a difficult-to-treat bacterial infection, and…

Researchers Probe Targets to Reduce Mucus Production

Yap and Taz — two proteins involved in lung injury responses and regeneration — suppress the maturation of mucus-producing goblet cells and limit mucus levels in the lungs, according to a study of mice. These findings suggest that promoting Yap/Taz’s activity may be a potential therapeutic approach to limit the…

Nominations Open for 2022 Eurordis Black Pearl Awards

Nominations are now open for the worldwide 2022 Black Pearl Awards from Eurordis-Rare Diseases Europe. The 12 award categories recognize individual advocates, policy makers, researchers, organizations, and companies who work to make a difference for the global rare disease community. The deadline for nominations is Sept. 10…

Airway Inflammation Affects pH, Response to CFTR Therapies

Inflammation in the airways of people with cystic fibrosis (CF) regulates the pH of the surface liquid and increases the response to approved CFTR modulators, a cell-based study suggested. Airway inflammation may be a key determinant in response to CF medicines, the researchers noted. “To advance personalized CFTR…

Data From Phase 2 Trials of ELX-02 Expected This Year

Eloxx Pharmaceuticals announced it expects to share data later this year from the first four treatment groups of a Phase 2 program evaluating the investigational therapy ELX-02 in people with cystic fibrosis (CF) who have at least one G542X mutation. “Given the substantial efforts of our clinical team,…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.